This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive
compensation for actions taken through them.
AbbVie Inc. (NYSE: ABBV) reported its second-quarter financial results before the markets opened on Friday. The biotech giant posted $1.42 in earnings per share (EPS) and $6.94 billion in revenue, which compares with consensus estimates from Thomson Reuters of $1.40 in EPS and revenue of $6.93 billion. The same period of last year reportedly had EPS of $1.26 and $6.43 billion in revenue.
During the second quarter, global Humira sales rose 13.7% to $4.716 billion on a reported basis, or 14.9% on an operational basis. At the same time, Humira sales in the United States increased 18% to $3.201 billion and international sales grew 9.1% to $1.515 billion.
Imbruvica net revenues totaled $626 million for the quarter, which was an increase of 42.6% year over year. U.S. sales totaled $528 million and international profit sharing tallied $98 million.
In terms of the outlook for the 2017 full year, AbbVie confirmed its EPS guidance of $5.44 to $5.54, representing growth of 13.9% at the midpoint. The consensus estimates from Thomson Reuters are $5.53 in EPS and $27.77 billion in revenue.
Richard A. Gonzalez, board chair and chief executive of AbbVie, commented:
We are pleased with the continued strength of our business. Our second quarter financial results reflected strong commercial and operational execution. We also remain very encouraged about the recent progress we’ve made with our late-stage pipeline, including strong results from a registrational trial of our selective JAK1 inhibitor, upadacitinib. We look forward to seeing data from numerous additional pivotal studies in the second half.
Shares of AbbVie were trading down about 2% at $70.24 on Friday, with a consensus analyst price target of $75.41 and a 52-week range of $55.06 to $75.04.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.